PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
Croyal M, Tran TT, Blanchard RH, Le Bail JC, Villard EF, Poirier B, Aguesse A, Billon-Crossouard S, Ramin-Mangata S, Blanchard V, Nativel B, Chemello K, Khantalin I, Thedrez A, Janiak P, Krempf M, Boixel C, Lambert G, Guillot E.
Croyal M, et al. Among authors: lambert g.
Clin Sci (Lond). 2018 May 31;132(10):1075-1083. doi: 10.1042/CS20180040. Print 2018 May 31.
Clin Sci (Lond). 2018.
PMID: 29724769